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We report the repeated isolation of the fungus Geosmithia argillacea from sputum samples of people with
cystic fibrosis. Identification was based on morphology and DNA sequence analysis. Isolation of G. argillacea
did not appear to be associated with clinical deterioration. The pathogenic potential of G. argillacea is
discussed.
People with cystic fibrosis (CF) are at risk of colonization by
and, in some cases, subsequent allergic reaction to or infection
with a number of fungi. Most notable among these are As-
pergillus species, Scedosporium apiospermum, and Exophiala
dermatitidis (7). Recently, the fungus Geosmithia argillacea has
been repeatedly isolated from sputum of several people with
CF attending clinics at the Leeds Regional Cystic Fibrosis
Centre. This report describes these findings and associated
clinical features and discusses their possible clinical signifi-
cance.
Approximately 500 subjects (150 pediatric and 330 adult)
with a confirmed diagnosis of CF attending clinics at the Leeds
Teaching Hospitals Trust were examined between 1 January
2005 and 30 June 2007. Sputum culture was carried out fol-
lowing treatment with 0.1% (wt/vol) solution of dithiothreitol
inoculated onto Sabouraud’s agar plates with 20 mg/liter colis-
tin and gentamicin (E&O Laboratories) and incubated at 29,
36, and 45°C for 7 days. A relatively slow-growing, pale-brown,
powdery mold was isolated from sputum samples of eight CF
subjects (Fig. 1a), in many cases from several sputum samples
from the same person (Table 1). Growth was seen on plates
incubated at all temperatures, in some cases with other fungi
(Table 1). Microscopic examination of cultures revealed an
extensively sporing, Penicillium-like fungus with phialides pro-
duced in a terverticillate mode of branching (Fig. 1b). Phialides
were cylindrical with tapering apices and produced chains of
columnar or “box-shaped” conidia that later became ovoid to
globose (Fig. 1c). This fungus also grew on Columbia blood
agar at a slightly lower rate than it did on Sabouraud’s agar.
Molecular identification was carried out as described previ-
ously (1, 2). Briefly, DNA was extracted from fungal cultures
and subjected to PCR using primers designed to amplify large
subunit (LSU) or internal transcribed spacer 1 (ITS1) regions
of the nuclear rRNA gene cassette (1). For certain isolates,
regions of the -tubulin gene were also analyzed. Sequences of
the PCR amplicons were used to search the GenEMBL data-
base and a database generated by the HPA Mycology Refer-
ence Laboratory, Bristol, United Kingdom. The sequences
from all three strains shared very high homologies with Geo-
smithia argillacea sequences in the public databases. A repre-
sentative isolate of G. argillacea from the present study has
been stored in the National Collection of Pathogenic Fungi
(NCPF) as NCPF 7710. Antifungal susceptibility testing of
representative G. argillacea isolates was performed according
to the CLSI M38-A methodologies (4). G. argillacea exhibited
low MICs to amphotericin B, itraconazole, posaconazole, and
caspofungin but high MICs to voriconazole (16 mg/liter) (Ta-
ble 2).
The clinical characteristics of CF subjects from whom G.
argillacea had been isolated were examined for any apparent
associated decline in clinical status and to establish any other
relevant clinical associations (Table 1). The first recognized
isolation of G. argillacea in CF sputum culture at this center
coincided with results determined by a different unit within the
Department of Microbiology carrying out identification of fil-
amentous fungi. It is likely that G. argillacea was present prior
to the study period but not recognized or reported as such. No
association between isolation of G. argillacea and either age or
lung function was apparent. There was no subjective evidence
of clinical decline in these subjects that could be attributed to
G. argillacea upon detailed review of the case notes. No obvi-
ous epidemiological links could be identified between people
with CF with positive sputum culture for G. argillacea. The
subjects were distributed widely throughout the catchment
area for the CF clinics involved; they included both pediatric
and adult patients with CF, and as such, they would have been
seen at different clinics and by different clinicians; and there
was no evidence that acquisition of G. argillacea correlated
with bronchoscopy. A full analysis of risk factors will be re-
quired in order to determine why we were able to grow G.
argillacea from samples from some people with CF and not
from those of others.
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Previously, G. argillacea, which is related to Penicillium, has
been described as a causal agent of food spoilage, where its
heat resistance was also noted (10). We assume that the sub-
jects in the current report acquired G. argillacea through inha-
FIG. 1. Morphology of G. argillacea. (a) Photograph of plate of G.
argillacea growing on Sabouraud dextrose agar after 7 days at 37°C. (b)
Microscopic appearance of the conidiophore and conidia of G. argil-
lacea. Bar  5 m. (c) Microscopic appearance of conidia of G.
argillacea.
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lation, though the precise environmental source is unknown.
However, we cannot formally rule out that isolation resulted
from contamination from food via the oropharynx as the qual-
ity of sputa was not routinely assessed. Recently Giraud et al.
(5) have determined that a fungus initially identified as Peni-
cillium emersonii in a patient with CF (3) was in fact G. argil-
lacea and that this organism is isolated increasingly from sputa
in people with CF in France. The only report of G. argillacea
causing a disseminated fungal infection to date has been one of
infection in a dog (6).
It is possible that G. argillacea may be isolated more com-
monly than has been realized up to now and overlooked given
its morphological similarities to Penicillium and Paecilomyces
spp. A molecular characterization of fungal isolates stored in
the NCPF that might represent misidentified G. argillacea iso-
lates supports this contention. Isolate NCPF 2801, from spu-
tum of a CF patient from the United Kingdom in 1991, was
indistinguishable genetically from G. argillacea (data not
shown), and G. argillacea was recently isolated from a bron-
choalveolar lavage specimen from a 51-year-old patient in
Leeds without CF being treated for a persistent cough follow-
ing smoke inhalation. Furthermore, two more isolates, NCPF
7594 and 7596, isolated from blood culture and peritoneal
dialysis fluid from a patient from the United Kingdom with
peritonitis in 2001 were also revealed to be G. argillacea by
-tubulin gene sequencing (data not shown).
While it appears that colonization of people with CF by G.
argillacea does not present a significant clinical problem, a
concern remains where people with CF become immunocom-
promised, for example, if they undergo lung transplantation.
Aspergillus fumigatus and Scedosporium apiospermum have
been documented to cause invasive disease that is frequently
fatal in this clinical setting (8, 9). It remains possible that G.
argillacea might cause systemic disease when colonized patients
become immunocompromised following lung transplantation.
It is pleasing to note, however, that subsequent to the study
period, two of the CF patients have undergone heart lung
transplantation at another center, and to date, there was no
evidence of systemic fungal infection by G. argillacea posttrans-
plantation in either patient.
Nucleotide sequence accession numbers. Sequences from
the G. argillacea isolates described here have been deposited
into GenBank under accession numbers AM744972 to
AM744975.
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TABLE 2. Antifungal susceptibility of G. argillacea isolates to amphotericin B, itraconazole, voriconazole, posaconazole, and caspofungin
obtained using the NCCLS/CLSI broth microdilution methoda
Isolate Source
MIC (mg/liter) for:
Amphotericin Itraconazole Voriconazole Caspofungin Posaconazole
NCPF 2801 Sputum, CF patient, UK, 1991 1 0.5 16 2 ND
NCPF 7594 Isolated from blood culture, patient with
peritonitis, UK, 2002
2 0.5 16 0.5 ND
NCPF 7596 Isolated from peritoneal dialysis fluid of same
patient as NCPF 7594
2 0.5 16 0.25 ND
CF isolate 1 Leeds Teaching Hospitals Trust, CF subject 4 0.5 0.5 16 0.25 0.5
CF isolate 2 Leeds Teaching Hospitals Trust, CF subject 3 2 0.5 16 0.5 0.5
a UK, United Kingdom; ND, not determined.
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